Overview
Interstitial Lung Disease: A Year in Review
ILD eNewsletter
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
This text-based activity will focus on the benefits of early diagnosis and appropriate treatment modalities for managing patients with interstitial lung disease (ILD). It will educate clinicians on recognizing varied disease presentations, mechanisms associated with the disease, common complications and improved drug delivery methodologies. It includes images, charts and audio clips featuring faculty commentary.
This activity is intended for pulmonologists, rheumatologists and other clinicians involved in the management of patients with Interstitial Lung Disease (ILD).
Interstitial lung disease (ILD) represents a large, heterogeneous group of more than 200 different entities. Idiopathic pulmonary fibrosis and connective tissue disease-associated ILD account for the majority of cases and are associated with significant morbidity and mortality. Despite the availability of guidelines, patients report delays in receiving a diagnosis and initiation of therapy. A prompt, accurate diagnosis is needed to ensure use of appropriate therapy. This eNewsletter will update clinicians on new and emerging science in the field of ILD, including application of emerging agents into treatment plans.
Upon completion of this activity, participants will be able to:
• Outline the diagnostic workup and the role of the multidisciplinary team in ensuring an accurate diagnosis of ILD, including IPF and CTD-ILD
• Discuss available guidelines and approaches for the management of patients with IPF and CTD-ILD
• Review patient needs and considerations for improving the patient-physician dialogue
• Outline the diagnostic workup and the role of the multidisciplinary team in ensuring an accurate diagnosis of ILD, including IPF and CTD-ILD
• Discuss available guidelines and approaches for the management of patients with IPF and CTD-ILD
• Review patient needs and considerations for improving the patient-physician dialogue
This activity is sponsored by The Academy for Continued Healthcare Learning
This activity is supported by an educational grant from Boehringer-Ingelheim Pharmaceuticals, Inc.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Imre Noth, MD
Professor of Medicine
Director, Bronchoscopy
Director, Interstitial Lung Disease Program
The University of Chicago Medicine
Chicago, IL
Professor of Medicine
Director, Bronchoscopy
Director, Interstitial Lung Disease Program
The University of Chicago Medicine
Chicago, IL
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.
The following financial relationships have been provided:
Imre Noth, MD (Chair)
Advisory Board, Honoraria Recipient and Speakers Bureau: Boehringer-Ingelheim and Genentech
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Investigational agents for IPF and CTD-ILD.
The following financial relationships have been provided:
Imre Noth, MD (Chair)
Advisory Board, Honoraria Recipient and Speakers Bureau: Boehringer-Ingelheim and Genentech
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Investigational agents for IPF and CTD-ILD.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pre-test, view the online eNewsletter and complete the post-test and evaluation form. To receive credit, 75% must be achieved on the post-test. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Inquiries may be directed to ACHL at (877) 444-8435, ext. 228.
Inquiries may be directed to ACHL at (877) 444-8435, ext. 228.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.